Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Immune Pharma
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Immune Pharma is developing immunotherapeutic agents with an advanced pipeline including a monoclonal antibody (bertilimumab) for autoimmune skin and GI diseases, a topical nano-formulation of cyclosporine for dermatological indications, and other assets in neurology and oncology. Key programs are in Phase 2 for bullous pemphigoid and ulcerative colitis. The company also has a recently spun-off oncology subsidiary, Cytovia, focused on AML with Ceplene[4].
- Therapeutic areas
- CardiovascularGastroenterologyNeurologyDermatologyOncology
- Modalities
- Monoclonal AntibodySmall MoleculeTopical FormulationAntibody
- Industry
- Biotech
02
Partnerships
Meda Pharma (now part of Mylan, now Viatris)Pint Pharma International
Beyond the preview
Go deeper on Immune Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immune Pharma.